Sandoz Group AG
Research Sandoz Group AG (SDZ) on Bullrun: market cap CHF 29.65B, P/E 56.2, dividend yield 1.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSDZ
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCHF
- Market capCHF 29.65B
- P/E56.2
- Dividend yield1.1%
- Financial periodFY2025
- RevenueUSD 11.16B
- Revenue growth7.4%
- Net incomeUSD 914.00M
- Free cash flowUSD 810.00M
- Gross margin47.4%
Valuation Snapshot
latest market cap is CHF 29.65B; P/E is 56.2; dividend yield is 1.1%.
Peer valuation comparison
Latest P/E is 56.16x versus a Healthcare sector median of 24.61x (128.2% above).
Latest dividend yield is 1.12% versus a Healthcare sector median of 1.84% (39.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 11.16B | USD 914.00M | USD 810.00M | 47.4% | 2.09 | USD 1.74B | USD 5.68B | USD 9.38B |
| FY2024 | USD 10.38B | USD 0 | USD 60.00M | 47.4% | 0 | USD 1.19B | USD 4.85B | USD 8.16B |
| FY2023 | USD 9.98B | USD 77.00M | -USD 263.00M | 45.7% | 0.18 | USD 1.11B | USD 4.55B | USD 8.65B |
| FY2022 | USD 9.31B | USD 848.00M | USD 796.00M | 47.0% | 1.97 | USD 74.00M | USD 333.00M | USD 8.75B |
| FY2021 | USD 9.68B | USD 908.00M | n/a | 47.5% | n/a | USD 40.00M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | CHF 29.65B | 56.2 | 1.2% | 0.8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.8 CHF, yield 1.1%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.6 USD |
| FY2024 | 0.45 USD |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
ETFs that hold Sandoz Group AG
Sandoz Group AG is one of the ten largest holdings of 10 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| UBS SPI ESG ETF CHF acc | 1.97% | 0.12% |
| UBS SMIM ETF CHF dis | 10.66% | 0.25% |
| UBS MSCI Switzerland IMI Socially Responsible ETF CHF dis | 4.32% | 0.28% |
| Swisscanto (CH) ESGen SDG Index Equity Switzerland ETF EA CHF | 4.23% | 0.35% |
| iShares MSCI Europe Mid Cap UCITS ETF EUR (Acc) | 1.51% | 0.15% |
| Deka MSCI Europe MC UCITS ETF | 1.52% | 0.36% |
| Saturna Al-Kawthar Global Focused Equity UCITS ETF | 3.30% | 0.75% |
| UBS SPI ESG ETF CHF dis | 1.97% | 0.12% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sandoz Group AG's market cap?
Sandoz Group AG's market capitalization is CHF 29.65B.
What is Sandoz Group AG's P/E ratio?
Sandoz Group AG's price-to-earnings (P/E) ratio is 56.2.
Does Sandoz Group AG pay a dividend?
Sandoz Group AG has a dividend yield of 1.1%.
What does Sandoz Group AG do?
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines.